Latest revenue
$186.7M
as of 2026-03-31
Latest net income
$-17.1M
as of 2026-03-31
Net margin
-9.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.20B
- Enterprise value
- $1.20B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $13.74
- 52-wk low
- $4.72
- Beta
- —
- Shares out
- 130.2M
5-year trend
What this company does
Table of Contents NEOGENOMICS, INC. PART I ITEM 1. BUSINESS NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Company” or collectively with its subsidiaries as “NeoGenomics,” “we,” “us,” or “our” in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “NEO.” Overview NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a…
AI summary unavailable — showing raw filing excerpt
Generated from NEO's filing dated 2026-02-17
Key risks
Table of Contents NEOGENOMICS, INC. ITEM 1A. RISK FACTORS We are subject to various risks that may materially harm our business, financial condition, and results of operations. They are not, however, the only risks we face. Additional risks and uncertainties not presently known to us or that we currently believe not to be material may also adversely affect our business, financial condition, or results of operations. An investor should carefully consider the risks and uncertainties described below and the other information in this filing before deciding to purchase our common stock. If any of these risks or uncertainties actually occurs, our business, financial condition, or operating…
AI summary unavailable — showing raw filing excerpt
Generated from NEO's filing dated 2026-02-17
Profitability
Gross margin
43.2%
1.6%Operating margin
-15.9%
14.3%Net margin
-14.9%
24.6%Return on equity
-12.9%
54.4%Return on assets
-7.9%
65.3%Leverage
Debt / equity
0.63×
15.4%Long-term debt / equity
0.00×
Debt / assets
38.5%
9.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $186.7M | +11.1% | $-17.1M | +34.0% | -9.2% |
Q4 2025 2025-12-31 | $190.2M | +10.6% | — | — | — |
Q3 2025 2025-09-30 | $187.8M | +11.9% | — | — | — |
Q2 2025 2025-06-30 | $181.3M | +10.2% | — | — | — |
Q1 2025 2025-03-31 | $168.0M | +7.5% | $-25.9M | +4.2% | -15.4% |
Q4 2024 2024-12-31 | $172.0M | — | $-15.3M | — | -8.9% |
Q3 2024 2024-09-30 | $167.8M | +10.4% | $-17.7M | +4.4% | -10.5% |
Q2 2024 2024-06-30 | $164.5M | +12.0% | $-18.6M | +23.4% | -11.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Testing Laboratories · SIC 8734
Your notes
Keep private notes on NEO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$250.3K
Insider selling
$576.9K
Net activity
−$326.6K
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-01-20 | Warren Stone Pres & Chief Operating Officer | Sale | 22,128 | $12.50 | $276.7K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns NEO
Institutional value
$419.4M
Total shares held
59.7M
Distinct holders
142
-115 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 20.0M | $148.1M | +496.2K (+2.5%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7.6M | $56.6M | — | New |
| 3 | FIRST TRUST ADVISORS LP | 6.2M | $45.7M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5.7M | $42.0M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 2.7M | $19.8M | +225.6K (+9.2%) | Added |
| 6 | abrdn plc | 2.0M | $15.0M | +228.0K (+12.7%) | Added |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 938.1K | $7.0M | +60.1K (+6.8%) | Added |
| 8 | VANGUARD FIDUCIARY TRUST CO | 847.3K | $6.3M | — | New |
| 9 | Granite Investment Partners, LLC | 752.5K | $5.6M | — | New |
| 10 | Bank of New York Mellon Corp | 714.4K | $5.3M | -25.7K (-3.5%) | Trimmed |
| 11 | PRINCIPAL FINANCIAL GROUP INC | 629.3K | $4.7M | +12.4K (+2.0%) | Added |
| 12 | CITIGROUP INC | 616.8K | $4.6M | +585.7K (+1881.9%) | Added |
| 13 | JPMORGAN CHASE & CO | 605.7K | $4.4M | +21.6K (+3.7%) | Added |
| 14 | HighMark Wealth Management LLC | 579.8K | $4.3M | +12.5K (+2.2%) | Added |
| 15 | Invesco Ltd. | 562.5K | $4.2M | +23.3K (+4.3%) | Added |
| 16 | SEI INVESTMENTS CO | 466.2K | $3.5M | +355.4K (+320.7%) | Added |
| 17 | Public Sector Pension Investment Board | 462.9K | $3.4M | +15.2K (+3.4%) | Added |
| 18 | Nuveen, LLC | 419.4K | $3.1M | -4.1K (-1.0%) | Trimmed |
| 19 | RHUMBLINE ADVISERS | 364.0K | $2.7M | +6.8K (+1.9%) | Added |
| 20 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 359.9K | $2.7M | +9.1K (+2.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once NEO's latest filing finishes processing.